How to Choose Between Open Access and Subscription-Based Journals for Clinical Manuscripts

One of the most critical decisions for clinical trial professionals and medical writers is choosing the right journal for manuscript submission. With the growth of scientific publishing, authors must navigate between open access (OA) and subscription-based journals. Each option has unique advantages and trade-offs related to accessibility, visibility, cost, and compliance.

This guide walks you through how to evaluate and select the most appropriate publishing model based on your research goals, target audience, sponsor requirements, and journal characteristics. It aligns with evolving expectations from regulators like EMA for greater transparency and public availability of clinical trial data.

Understanding the Two Publishing Models:

Open Access Journals:

OA journals make articles freely available to all readers without subscription. Authors usually pay an Article Processing Charge (APC).

• Free public access immediately upon publication
• High visibility and global reach
• Authors retain copyright under Creative Commons licenses
• Often supported by universities, funders, or government mandates
• APC may be waived for some authors (low-income countries, grants)

Subscription-Based Journals:

These journals restrict access to paying subscribers. Authors generally do not pay to publish.

• Access limited to subscribers or institutions
• No APC, but may charge for color figures or excess pages
• Often carry higher impact factors or prestige
• Delays in public availability of research
• Limited citation and media reach

Key Factors to Consider When Choosing:

1. Target Audience Reach:

If your research is intended to influence global practice, guidelines, or policymaking, OA maximizes readership. Readers in resource-limited settings without institutional subscriptions can freely access your work. OA is highly recommended for Stability Studies or trial results with public health relevance.

2. Sponsor and Funder Requirements:

Many public and private sponsors now mandate OA publishing. Examples include:

• NIH (USA), Wellcome Trust, Bill & Melinda Gates Foundation
• EU Horizon 2020 and similar research initiatives
• Pharma companies promoting transparency of trial data

Check the sponsor’s publication policy before choosing a journal.

3. Budget and Publication Charges:

OA journals charge APCs ranging from $500 to $5000 depending on the journal’s impact factor and publisher. While some journals offer waivers, authors without funding may struggle with these fees. In contrast, subscription-based journals usually do not charge authors (though page/figure fees may apply).

Some hybrid journals offer both models—subscription with optional OA by paying APCs.

4. Journal Impact and Indexing:

Subscription-based journals often have longer histories and higher impact factors, making them attractive for career progression. However, many OA journals (e.g., PLOS ONE, BMC, Frontiers) are now indexed in PubMed, Scopus, and have strong citation metrics.

Whether you publish OA or not, ensure the journal is peer-reviewed and indexed in reputable databases to preserve scientific credibility.

Advantages of Open Access Publishing:

• Increased visibility and citations
• Faster dissemination of results
• Supports equity and democratization of knowledge
• Mandatory under many transparency frameworks for clinical research
• Enables public scrutiny and ethical accountability of pharma trials

Studies have shown that OA articles receive significantly more downloads and social media engagement compared to paywalled ones.

Limitations and Risks of Open Access:

• High APCs may not be affordable without grant support
• Quality varies widely across OA journals—watch for predatory publishers
• Newer OA journals may lack established impact metrics
• Peer-review timelines may be shorter, but not always transparent

To avoid predatory journals, check membership in DOAJ, COPE, and publisher reputation before submission.

When to Prefer Subscription-Based Journals:

Choose a subscription-based journal if:

• You’re targeting a high-impact, field-specific audience
• Your institution has access to that journal and broad readership
• You have no funds for APCs and no mandate for OA
• Your manuscript addresses niche regulatory issues (e.g., pharma regulatory requirements)

Comparison Table: Open Access vs Subscription

Hybrid Journals – A Middle Ground:

Many high-impact journals now offer OA options under a hybrid model. Authors can choose to publish OA by paying APCs or go the traditional route. These provide the best of both worlds—prestige and accessibility.

Examples: The Lancet, NEJM, JAMA Network Open

Best Practices for Choosing the Right Journal:

1. Match your manuscript topic with the journal scope and audience
2. Check indexing and peer review rigor
3. Evaluate APCs and funding availability
4. Ensure ethical publishing policies (COPE member, transparent fees)
5. Confirm compliance with sponsor or institutional mandates

You can also refer to publishing support resources on Pharma SOPs and follow guidelines for manuscript preparation based on validation master plans or trial protocols.

Conclusion:

There is no one-size-fits-all answer when choosing between open access and subscription-based journals. The best choice depends on your manuscript’s audience, funding support, sponsor policy, and strategic goals. Open access enhances global reach and aligns with current trends in GMP compliance transparency, while subscription journals may offer prestige and history.

Make an informed decision based on journal quality, accessibility, and your publishing priorities. A well-placed manuscript can maximize impact, citations, and influence in the pharmaceutical and clinical research community.

Establishing Ethical Authorship in Clinical Trial Manuscripts

Clear authorship criteria and publication ethics are essential in clinical research to ensure transparency, accountability, and credibility of scientific findings. In the pharmaceutical industry, compliance with ethical standards in manuscript writing prevents misconduct, builds public trust, and aligns with international regulatory expectations. This guide walks clinical trial professionals and pharma writers through the ethical landscape of manuscript authorship, following globally recognized frameworks such as ICMJE guidelines.

Platforms like StabilityStudies.in reinforce ethical publishing practices in parallel domains like stability data reporting—emphasizing the importance of consistency across pharmaceutical documentation.

Understanding ICMJE Authorship Criteria:

The International Committee of Medical Journal Editors (ICMJE) provides widely accepted authorship criteria to determine who qualifies as an author. According to ICMJE, authorship should be based on the following four criteria:

1. Substantial contributions to the conception or design of the work, or data acquisition, analysis, or interpretation
2. Drafting the work or revising it critically for important intellectual content
3. Final approval of the version to be published
4. Agreement to be accountable for all aspects of the work, ensuring questions related to its accuracy or integrity are appropriately resolved

All four criteria must be met. Individuals who meet only some of these should be acknowledged, not listed as authors.

Avoiding Ghostwriting and Guest Authorship:

Two major violations in publication ethics are ghostwriting and guest (or honorary) authorship:

• Ghostwriting: Involves writing the manuscript without proper acknowledgment of the contributor, often in the context of commercial influence
• Guest authorship: Includes listing individuals as authors who did not make substantial contributions

Both practices are unethical and breach transparency guidelines. Journals are increasingly requiring author contribution statements to counter these issues.

To ensure transparency, authorship practices should be documented, ideally using SOPs for pharma SOP documentation that include ethical authorship as a defined process.

Clarifying Author Contributions with CRediT Taxonomy:

The Contributor Roles Taxonomy (CRediT) is a structured way to describe each author’s role, covering 14 contributor types such as:

• Conceptualization
• Methodology
• Formal analysis
• Investigation
• Writing – Original Draft
• Writing – Review & Editing
• Supervision
• Funding Acquisition

Including a CRediT statement with the manuscript increases accountability and clarifies contributions. Many journals now require it during submission.

Determining the Order of Authors:

Author order should reflect the relative contribution of each person. First authors typically perform most of the work and writing, while senior authors may appear last as supervisors or principal investigators. Intermediate authors contribute in various capacities.

Best practices include:

1. Discuss author order early in the project
2. Update order if roles change during manuscript development
3. Document agreement among all authors regarding order

Disputes often arise due to unclear expectations or lack of documentation—use internal SOPs or publication policies to avoid ambiguity.

Manuscript Approval and Accountability:

Before submission, all listed authors must:

• Review and approve the final manuscript version
• Confirm agreement with content, data integrity, and conclusions
• Accept responsibility for their contributions and ensure ethical compliance

This ensures that everyone is accountable and the publication is ethically sound. Journals may request confirmation of author approvals as part of submission requirements.

Managing Authorship in Multi-Sponsor and Multinational Trials:

Large-scale clinical trials often involve multiple institutions, CROs, or sponsors. Authorship must reflect true scientific contribution rather than organizational affiliation.

Best practices include:

• Use joint authorship committees or publication steering committees
• Follow a pre-agreed authorship plan, often outlined in the trial protocol
• Balance contributions from all involved stakeholders
• Avoid giving undue authorship to funding sponsors unless justified

For example, in accordance with EMA guidance, transparent authorship disclosures support scientific credibility in regulatory submissions.

Acknowledgments and Non-Author Contributions:

Contributors who do not meet ICMJE authorship criteria should be acknowledged appropriately. This includes:

• Medical writers (if not meeting full authorship criteria)
• Statisticians providing analysis but not intellectual content
• Study coordinators or technical support staff

Always obtain written permission from individuals before acknowledging them in a publication.

Handling Authorship Disputes and Corrections:

Despite precautions, disputes over authorship can occur. Institutions and research teams should have formal procedures in place to resolve conflicts. Corrective actions may include:

• Retraction of the manuscript
• Erratum or correction notices
• Reporting to journals or funding agencies

Using SOPs in accordance with GMP documentation standards can ensure consistency and fairness in resolution.

Ethical Publication Practices – Summary Checklist:

• Follow ICMJE’s four authorship criteria
• Avoid ghost and honorary authorship
• Use CRediT taxonomy for contribution disclosure
• Discuss and agree author order in advance
• Document all contributions and approvals
• Maintain transparency in multinational collaborations
• Acknowledge non-author contributors appropriately
• Resolve disputes through documented procedures

Conclusion:

Ethical authorship is a cornerstone of scientific integrity in clinical trial reporting. Pharma professionals must uphold these standards not just to comply with guidelines, but to foster a culture of trust and transparency. Incorporating authorship SOPs and aligning with platforms like pharma validation and pharma regulatory compliance ensures that manuscripts are credible, accountable, and ethically sound.

How to Choose the Best Journal for Your Clinical Trial Publication

Publishing clinical trial results in the right journal can amplify the scientific impact, meet sponsor expectations, and comply with regulatory requirements. But with thousands of journals available, targeting the best one requires a strategic and systematic approach. This tutorial provides a step-by-step guide to help pharma professionals and clinical trial experts select the most suitable journal for their manuscript submission.

As part of the broader scientific and regulatory documentation framework supported by platforms like StabilityStudies.in, journal targeting plays a vital role in scientific communication and evidence dissemination.

Step 1: Understand the Study’s Scope and Relevance:

Start by analyzing the clinical trial’s therapeutic area, phase, intervention type, patient population, and outcome significance. These factors determine journal eligibility and reader interest.

• Is the trial early-phase or confirmatory?
• Does it address a high-burden disease area?
• Are the results statistically and clinically significant?
• Do findings introduce a novel mechanism, therapy, or comparison?

Understanding your trial’s scientific value helps align it with journals that publish similar content.

Step 2: Define the Target Audience:

Identify who should read your published results—clinicians, regulatory experts, policy makers, researchers, or industry sponsors.

1. If targeting practitioners, choose clinically oriented journals
2. If appealing to regulators or payers, opt for policy or pharmacoeconomic journals
3. If focusing on academic or investigational audiences, consider specialty or basic science journals

Matching audience expectations with journal readership improves reach and engagement.

Step 3: Search and Shortlist Candidate Journals:

Use databases like PubMed, Scopus, and Web of Science to find journals that have published studies similar to yours. Review where competitors or peers have published.

Key selection parameters include:

• Impact factor and citation metrics
• Journal scope and topic fit
• Publication frequency and backlog
• Open access availability
• Acceptance rate and review timelines

Document your findings in a comparison table for decision-making.

Step 4: Review the Author Guidelines:

Every journal has detailed instructions for manuscript format, word count, references, ethical compliance, and data presentation.

• Check maximum length for articles and abstracts
• Understand reference citation style (e.g., AMA, Vancouver)
• Review figure/table limits and resolution requirements
• See if the journal accepts supplements or online appendices

Align your manuscript template with the guidelines early to avoid rework.

Step 5: Consider Open Access vs. Subscription Journals:

Open access journals make articles freely available, potentially increasing visibility and citations. However, they often charge article processing fees (APCs).

Evaluate the pros and cons:

1. Open access journals promote global reach
2. Subscription journals may have higher impact factors
3. Hybrid journals offer both options
4. Some sponsors or institutions fund APCs for open access

Ensure transparency in cost disclosures and funding acknowledgments.

Step 6: Ensure Ethical and Regulatory Fit:

Target journals that uphold ethical standards and align with CDSCO or USFDA publishing norms.

• Require trial registration (e.g., ClinicalTrials.gov)
• Comply with ICMJE authorship rules
• Support CONSORT/PRISMA reporting guidelines
• Accept redacted CSRs and data transparency policies

This ensures that your publication meets both scientific and regulatory expectations.

Step 7: Evaluate Journal Review Timelines and Processes:

Some journals offer fast-track options, especially for high-impact or time-sensitive trials. Review the journal’s peer review process for transparency and timeliness.

Consider:

• Time from submission to decision
• Availability of preprints or online-first publishing
• Level of editorial support or language editing
• Revision requirements and reviewer response expectations

Avoid journals with lengthy or unclear processes if speed is critical.

Step 8: Use Journal Match Tools:

Several tools help identify journals based on abstract, title, or keywords:

• Elsevier Journal Finder
• Springer Journal Suggester
• JANE (Journal/Author Name Estimator)
• Wiley Journal Finder

These tools improve accuracy in journal targeting and can complement manual search strategies.

Step 9: Avoid Predatory Journals:

Be cautious of journals that promise fast publication without rigorous peer review. Check the Beall’s List or consult institutional publishing guidelines.

Red flags include:

• No clear peer-review policy
• Unrealistic timelines (e.g., 24 hours to publish)
• Unverifiable editorial board
• Generic or spam-like emails inviting submissions

Maintain credibility by publishing only in recognized, indexed journals.

Step 10: Finalize and Submit:

After shortlisting, rank journals based on fit, quality, timelines, and feasibility. Submit to your first-choice journal, ensuring all components are ready:

• Cover letter with study highlights and journal alignment
• Manuscript formatted to guidelines
• Declarations and ethical approvals
• ICMJE forms or disclosures as needed

If rejected, revise and resubmit promptly to the next journal on your list.

Conclusion:

Choosing the right journal for your clinical trial publication is a critical step in the scientific communication lifecycle. By systematically evaluating scope, audience, ethical fit, timelines, and indexing status, pharma professionals can enhance visibility, citations, and regulatory value. Align this approach with structured documentation frameworks like those in pharma validation and pharma regulatory compliance for long-term publishing success.